Monday, 16 Sep 2019

You are here

RheumNow Podcast – TNFs and the Inflammasome (1.25.19)

Dr Jack Cush reviews the news from the past week at RheumNow.com.

  1. Meta-analysis of 4719 elderly RA/IBD/PSO pts on biologics vs 13,305 younger vs 3961 older patients (no biologics) shows biologic use in elderly to be assoc w/ an increased risk of infections (3.6 fold increase in risk) but no increase in cancer or death https://t.co/pWtMMo2KQ1
  2. Using FMF-KI knockout mice (high TNF levels) researchers find TNF signaling drives pyrin & inflammasome activation; TNF is a critical modulator of pyrin of pyrin-inflammasomopathies like FMF. This is why TNF inhib sometimes work in inflammasomopathies. https://t.co/0EvuTI57tn
  3. Systematic review of literature and 478 RA patients (mostly female; age 53-64 yrs) shows 73 to 97% of patients being unaware of an increased risk of developing Cardiovascular Disease in relation to their RA, https://t.co/aNM3wI2KBo
  4. JAMA study shows that when drug companies increased their opioid marketing budgets by just $5.29 per 1,000 population, the number of MD opioid prescriptions went up 82% and opioid deaths increased 9%. https://t.co/4FAr53gH17 
  5. Using the 1998-2014 U.S. National Inpatient Sample- gout was associated with 9-20% higher healthcare utilization and 6% higher hazard of transfusion after primary hip replacement surgery. https://buff.ly/2U8wvwu
  6. Does Seropositivity Change with Therapy?
  7. Smoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Prior Authorizations Delay Care in Rheumatology

Physicians who believe their patients' health is negatively affected by insurers' demands for prior authorization, and the delays that often result, will find that opinion vindicated by a new study of rheumatology care: when permission had to be sought from insurers to provide intravenous drugs, average time to begin treatment was longer and patients had twice the corticosteroid exposure, a single-center analysis found.

Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis

The US Food and Drug Administration (FDA) on Friday, August 16, approved AbbVie JAK1 inhibitor, Rinvoq (upadacitinib) for adults with  rheumatoid arthritis with moderately to severely active disease either not responding to, or intolerant of, methotrexate (MTX). 

Are Non-TNF Biologics Superior to TNF inhibitors?

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis. An analysis from the Swedish Rheumatology Register shows that the non-TNFi biologic DMARDs (bDMARDs), in particular tocilizumab and rituximab, are more effective than TNFi. 

FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis

The FINCH2 study has shown that filgotinib, an oral once daily JAK 1 inhibitor, is highly effective in rheumatoid arthritis (RA) patients who failed to respond to prior biologic therapy.

Rituximab Safety Concerns when Used in anti-TNF Refractory RA

The SUNSTONE study evaluated the long‐term safety of rituximab in rheumatoid arthritis (RA) previously exposed to ≥1 anti–tumor necrosis factor inhibitors (TNFi) and showed a stable, but high, rate of serious infections, opportunistic infections and an overall higher mortality rate.